Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Inclusion Criteria: All subjects * Male and female Caucasian subjects between 18 and 79 years of age (both inclusive) with a body mass index above/equal 18.0 and below/equal 34.0 kg/m² Subjects with hepatic impairment * Subjects with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan * Subjects with hepatic impairment as per Child Pugh system * Subjects with stable liver disease during the last 2 months Healthy subjects * Healthy subjects with mean age and body weight not varying by more than ±10 years and ±10 kg from the groups of subjects with mild and moderate hepatic impairment, respectively. Exclusion Criteria: * Medical history of continent ileostomy. * Febrile illness within 1 week prior to admission to study center. * Known hypersensitivity to the study drug (active substances or excipients of the preparation). * Subjects with diagnosed malignancy within the past 5 years. * Use of any systemic or topical medicine or substances which oppose the study objectives or which might influence them, in particular: Starting from screening on, but minimum from 2 weeks before the study drug administration until the follow-up visit: * CYP3A4 inducers * CYP3A4 inhibitors * Potent CYP2C8 inhibitors * Major uridine diphosphate-glucuronosyltransferase isoenzyme 1A1 (UGT1A1) substrate (irinotecan) On the day of administration of neladenoson bialanate: * Major breast cancer resistance protein (BCRP) substrates * Regular daily consumption of more than 500 mL of usual beer or the equivalent quantity of of more than 2 units of alcohol in another form - Intake of ethanol containing food and beverages from 48 h prior to admission to the study center until 96 h after study drug administration, afterwards not more than 2 units of alcohol per day until follow-up examination. * Intake of food and beverages containing grapefruit or pomelo from 14 days prior to study drug administration up to the last time point of PK sampling. * Therapies (e.g. physiotherapy, acupuncture, etc.) within 1 week before study drug administration. * Positive urine drug screening. * Positive results for human immune deficiency - Abnormal (clinically significant) thyroid stimulating hormone (TSH).